Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.

Clémenson C, Liu W, Bricout D, Soyez-Herkert L, Chargari C, Mondini M, Haddad R, Wang-Zhang X, Benel L, Bloy C, Deutsch E.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1141-1152. doi: 10.1016/j.ijrobp.2019.04.031. Epub 2019 May 4.

PMID:
31063799
2.

CCR2-Dependent Recruitment of Tregs and Monocytes Following Radiotherapy Is Associated with TNFα-Mediated Resistance.

Mondini M, Loyher PL, Hamon P, Gerbé de Thoré M, Laviron M, Berthelot K, Clémenson C, Salomon BL, Combadière C, Deutsch E, Boissonnas A.

Cancer Immunol Res. 2019 Mar;7(3):376-387. doi: 10.1158/2326-6066.CIR-18-0633. Epub 2019 Jan 29.

PMID:
30696630
3.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
4.

The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy.

Clémenson C, Chargari C, Liu W, Mondini M, Ferté C, Burbridge MF, Cattan V, Jacquet-Bescond A, Deutsch E.

Mol Cancer Ther. 2017 Oct;16(10):2107-2119. doi: 10.1158/1535-7163.MCT-17-0112. Epub 2017 Jun 15.

5.

Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer.

Mondini M, Nizard M, Tran T, Mauge L, Loi M, Clémenson C, Dugue D, Maroun P, Louvet E, Adam J, Badoual C, Helley D, Dransart E, Johannes L, Vozenin MC, Perfettini JL, Tartour E, Deutsch E.

Mol Cancer Ther. 2015 Jun;14(6):1336-45. doi: 10.1158/1535-7163.MCT-14-1015. Epub 2015 Apr 1.

6.

Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.

Fumagalli I, Dugue D, Bibault JE, Clémenson C, Vozenin MC, Mondini M, Deutsch E.

Onco Targets Ther. 2015 Feb 2;8:335-45. doi: 10.2147/OTT.S68235. eCollection 2015.

7.

Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia.

Gachet S, Genescà E, Passaro D, Irigoyen M, Alcalde H, Clémenson C, Poglio S, Pflumio F, Janin A, Lasgi C, Dodier S, Soyer M, Duménil G, Ghysdael J.

Leukemia. 2013 Dec;27(12):2289-300. doi: 10.1038/leu.2013.156. Epub 2013 May 21.

PMID:
23689515
8.

IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.

Ferté C, Loriot Y, Clémenson C, Commo F, Gombos A, Bibault JE, Fumagalli I, Hamama S, Auger N, Lahon B, Chargari C, Calderaro J, Soria JC, Deutsch E.

Mol Cancer Ther. 2013 Jul;12(7):1213-22. doi: 10.1158/1535-7163.MCT-12-1067. Epub 2013 May 2.

9.

Understanding the functions of tumor stroma in resistance to ionizing radiation: emerging targets for pharmacological modulation.

Chargari C, Clemenson C, Martins I, Perfettini JL, Deutsch E.

Drug Resist Updat. 2013 Feb-Apr;16(1-2):10-21. doi: 10.1016/j.drup.2013.01.001. Epub 2013 Feb 20. Review.

PMID:
23434004
10.

Combination of vascular disrupting agents and ionizing radiation.

Clémenson C, Chargari C, Deutsch E.

Crit Rev Oncol Hematol. 2013 May;86(2):143-60. doi: 10.1016/j.critrevonc.2012.10.002. Epub 2012 Nov 20. Review.

PMID:
23177097
11.

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.

Clémenson C, Jouannot E, Merino-Trigo A, Rubin-Carrez C, Deutsch E.

Invest New Drugs. 2013 Apr;31(2):273-84. doi: 10.1007/s10637-012-9852-4. Epub 2012 Jul 19.

PMID:
22810221
12.

Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy.

Clémenson C, Chargari C, Désiré L, Casagrande AS, Bourhis J, Deutsch E.

Invest New Drugs. 2012 Dec;30(6):2173-86. doi: 10.1007/s10637-011-9785-3. Epub 2012 Jan 14. Erratum in: Invest New Drugs. 2012 Dec;30(6):2451-3.

PMID:
22246215
13.

DNA damage checkpoint inactivation: adaptation and recovery.

Clémenson C, Marsolier-Kergoat MC.

DNA Repair (Amst). 2009 Sep 2;8(9):1101-9. doi: 10.1016/j.dnarep.2009.04.008. Epub 2009 May 22. Review.

PMID:
19464963
14.

Supplemental Content

Loading ...
Support Center